Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: Kensey Nash

This article was originally published in The Gray Sheet

Executive Summary

Kensey Nash: Plans to go public via initial public offering of 2.7 mil. shares at $11 to $13 per share, the firm announces Oct. 27. The company is currently awaiting final FDA approval for its Angio-Seal hemostasis device after receiving a unanimous approval recommendation from FDA's Circulatory Systems Devices Panel in May ("The Gray Sheet" May 15, p. 8) and an approvable letter from the agency in July. Approximately $10 mil. of the anticipated proceeds from the offering would go toward R&D; $6.6 mil. would go toward debt repayment; $1.9 mil. would repay advances to the company from American Home Products, the firm's marketing and manufacturing partner for Angio-Seal; the remainder would go toward general corporate purposes. Managing underwriters are Janney Montgomery Scott, NatWest Securities Limited and Gerard Klauer Mattison & Co...

You may also be interested in...



UK Faces Distribution Challenges With Pfizer/BioNTech Vaccine

New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.

Global Pharma Guidance Tracker – November 2020

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Execs On The Move: New CEOs At Alpha Source And Mölnlycke; Xvivo Perfusion CFO Gets New Title

Alpha Source hired a new CEO from Mayline, while Mölnlycke’s CEO comes from CellaVision; Xvivo Perfusion finance chief changed job to become chief operating officer; Shire senior VP now COO at AVITA; and more.

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel